Piscataway, NJ, November 14, 2022–Camber Pharmaceuticals is pleased to announce the addition of Dabigatran Etexilate Capsules to its current portfolio.
Dabigatran Etexilate Capsules are a direct thrombin inhibitor, indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Dabigatran Etexilate Capsules from Camber are available in 75 and 150 mg strengths in 60 count bottles.
To find out more about Dabigatran Etexilate Capsules please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
